Lupin, TB Alliance partner for new therapy for highly drug-resistant TB

Indian pharma company Lupin Limited has secured a non-exclusive license from TB Alliance, a non-profit drug developer, for manufacturing the anti-TB drug pretomanid.

Pretomanid is part of the three-drug BPaL regimen (made up of bedaquiline, pretomanid, and linezolid), intended for the treatment of highly drug-resistant tuberculosis (TB).

Mel Spigelman — President and CEO of TB Alliance said: “TB Alliance is committed to ensure its products are widely available and affordable to those who need them.

“Partnering with Lupin, a well-established manufacturer with experience delivering high quality TB therapies, will help further enable widespread access to our novel regimen while promoting a competitive market to drive affordability.”

Lupin said that it plans to commercialize the anti-tuberculosis drug in nearly 140 countries and territories.

Nilesh Gupta — Managing Director of Lupin said: “As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health.”